News
Cancer Horizons
All News
Blogs
Caregiving
Diet and Exercise
Financial
Psychosocial
Recipes
Sexual Health
Side Effect
Sponsored
Survivorship
Videos
All Videos
CURE Connections
CURE Expert Connections®
CURE Speaking Out
CURE TV
Educated Patient Sound Bites
On Demand: Award Programs
On Demand: Patient Summits
On Demand: Webinars
Conferences
Conference Coverage
Conference Listing
Events
CURE Adventures
CURE Awards
Educated Patient Summits & Updates
Educated Patient Webinars
Resources
Advocacy Groups
Art Gallery
CURE Ambassador Program
Clinical Trial Corner
Educated Patient Research Updates
Journey
Partners
Podcasts
Publications
Share Your Story
Subscribe
CURE Magazine
HEAL Magazine
Sign Up for eNews

logo
Spotlight
Blogs
Cancer Horizons
Clinical Trial Corner
Publications
Recipes
Videos
Cancer Type
Bladder
Breast
CLL
Kidney
Lung
MCL
Ovarian
Prostate
Skin
About CURE
Press Releases
Share Your Story
Write for CURE
Cancer Horizons
All News
Blogs
Caregiving
Diet and Exercise
Financial
Psychosocial
Recipes
Sexual Health
Side Effect
Sponsored
Survivorship
All Videos
CURE Connections
CURE Expert Connections®
CURE Speaking Out
CURE TV
Educated Patient Sound Bites
On Demand: Award Programs
On Demand: Patient Summits
On Demand: Webinars
Conference Coverage
Conference Listing
CURE Adventures
CURE Awards
Educated Patient Summits & Updates
Educated Patient Webinars
Advocacy Groups
Art Gallery
CURE Ambassador Program
Clinical Trial Corner
Educated Patient Research Updates
Journey
Partners
Podcasts
Publications
Share Your Story
CURE Magazine
HEAL Magazine
Sign Up for eNews
Advertisement
Bladder Cancer
| Brain Cancer
| Breast Cancer
| Childhood Cancers
| Gastric Cancer
| Gynecologic Cancer
| Head & Neck Cancer
| Immunotherapy
| Kidney Cancer
| Leukemia
| Liver Cancer
| Lung Cancer
| Lymphoma Cancer
| MDS
| MPN
| Melanoma
| Mesothelioma
| Myeloma
| Prostate Cancer
| Rare Cancers
| Sarcoma
| Skin Cancer
| Testicular Cancer
| Thyroid Cancer
| Waldenström Macroglobulinemia
View All >>
  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Childhood Cancers
  • Gastric Cancer
  • Gynecologic Cancer
  • Head & Neck Cancer
  • Immunotherapy
  • Kidney Cancer
  • Leukemia
  • Liver Cancer
  • Lung Cancer
  • Lymphoma Cancer
  • MDS
  • MPN
  • Melanoma
  • Mesothelioma
  • Myeloma
  • Prostate Cancer
  • Rare Cancers
  • Sarcoma
  • Skin Cancer
  • Testicular Cancer
  • Thyroid Cancer
  • Waldenström Macroglobulinemia

SPOTLIGHT -

Blogs
| Cancer Horizons
| Clinical Trial Corner
| Publications
| Recipes
| Videos

Trial Underway for Novel Agent Plus Immunotherapy for HPV-Related Head and Neck Cancer

February 2, 2022
Brielle Benyon
Article

After preliminary results showed promise for the combination, researchers are expanding their clinical trial for PDS0101 plus Keytruda in HPV-related head and neck cancer.

Results from a phase 2 clinical trial demonstrated promise for the combination of the novel agent PDS0101 plus Keytruda (pembrolizumab) in treating human papillomavirus (HPV)-associated head and neck cancer. As such, the trial will now progress to full enrollment of 54 patients who have not been previously treated with a checkpoint inhibitor.

The trial, VERSATILE-002, involves two groups of HPV16-positive patients with head and neck cancer that is either metastatic or has returned after treatment. One group consists of patients who have no prior treatment with checkpoint inhibition immunotherapy, while the other group is made up of 21 patients whose disease failed checkpoint inhibition — assessment for this group is still ongoing.

In the checkpoint inhibitor-naïve group, four or more of the 17 patients achieved an objective response, which was classified by a 30% or more reduction in tumor size.

“The achievement of this important milestone in the VERSATILE-002 phase 2 clinical trial strengthens the evidence of our novel Versamune platform’s potential ability to induce high levels of tumor-specific CD8+ killer T-cells that attack the cancer to achieve tumor regression,” commented Dr. Lauren V. Wood, Chief Medical Officer of PDS Biotech, the developer of PFS101, in a statement. “The initial data solidifies our belief that PDS0101’s demonstrated preclinical efficacy when combined with Keytruda has the potential to significantly improve clinical outcomes for patients with advanced HPV16-positive head and neck cancers.”

PDS0101 works by inducing large quantities of CD4+ helper and CD8+ killer T cells, a type of white blood cells that are key in the functioning of the immune system. This works in tandem with checkpoint inhibitors like Keytruda, which help unmask the cancer cells to the immune system, allowing the body to find and fight the cancer.

Upcoming research will determine which regimen is better at fighting cancer: Keytruda plus PDS0101 or Keytruda alone. Eligible patients must have HPV16-positive head and neck cancer that has come back or spread, have recovered from complications from previous major surgeries or radiation and have good overall health, as determined by a blood test.

Patients on the trial are set to receive intravenous (IV) Keytruda every three weeks for up to 35 treatments (about two years). Those in the PDS0101 group are also anticipated to receive the drug, via IV, in combination with Keytruda for the first four cycles of treatment and again at cycle 12. The plan is for bloodwork to be conducted before and after each treatment, and patients should also undergo imaging studies every nine weeks for the first year so that their clinicians can evaluate the status of their cancer.

Treatment on the trial is planned to be administered until a patient experiences disease progression or until they received the maximum limit of 35 treatments.

The lead investigator of the expanded trial is Dr. Jared Weiss from the University of Carolina at Chapel Hill School of Medicine and Lineberger Comprehensive Cancer Center, but that does not mean that patients who are interested must be nearby. There are 27 sites across the U.S. that are involved in the trial. Patients interested in enrolling can email: info@pdsbiotech.com.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Related Videos
Dr. Michael Moore
Dr. Michael Moore
Dr. Michael Moore
Dr. Michael Moore
Dr. Michael Moore
Related Content

Eagles’ Hall of Famer Discusses Diagnosis, Toby Keith Gives Cancer Update and More

September 29th 2023

Author, Five-Time Cancer Survivor Shares His Experiences in New Book

August 10th 2023

AI Can Help Diagnose Sarcopenia in Patients with Head and Neck Cancer

August 18th 2023

A Powerful Voice in Head and Neck Cancer

April 16th 2020

Radiotherapy Technique May Prevent Swallow Dysfunction in Head and Neck Cancer

August 8th 2023

Ongoing Trial Investigates Cancer Vaccine Plus Keytruda for TNBC

August 7th 2023

Eagles’ Hall of Famer Discusses Diagnosis, Toby Keith Gives Cancer Update and More

September 29th 2023

Author, Five-Time Cancer Survivor Shares His Experiences in New Book

August 10th 2023

AI Can Help Diagnose Sarcopenia in Patients with Head and Neck Cancer

August 18th 2023

A Powerful Voice in Head and Neck Cancer

April 16th 2020

Radiotherapy Technique May Prevent Swallow Dysfunction in Head and Neck Cancer

August 8th 2023

Ongoing Trial Investigates Cancer Vaccine Plus Keytruda for TNBC

August 7th 2023

Eagles’ Hall of Famer Discusses Diagnosis, Toby Keith Gives Cancer Update and More

September 29th 2023

Author, Five-Time Cancer Survivor Shares His Experiences in New Book

August 10th 2023

AI Can Help Diagnose Sarcopenia in Patients with Head and Neck Cancer

August 18th 2023

A Powerful Voice in Head and Neck Cancer

April 16th 2020

Radiotherapy Technique May Prevent Swallow Dysfunction in Head and Neck Cancer

August 8th 2023

Ongoing Trial Investigates Cancer Vaccine Plus Keytruda for TNBC

August 7th 2023
Related Content
Advertisement

football image

Eagles’ Hall of Famer Discusses Diagnosis, Toby Keith Gives Cancer Update and More

September 29th 2023
Article

As Connor McGregor honors a fan who dies from cancer and Steve Scalise reveals information about his blood cancer, this is what’s happening in the oncology space this week.

Read More


Bill C. Potts holding his small dog, Pippa | Photo credit: Sarah Potts

Author, Five-Time Cancer Survivor Shares His Experiences in New Book

August 10th 2023
Podcast

Bill C. Potts, author and five-time cancer survivor, lends his experience and tips about cancer to others in his book, “Up for the Fight.”

Listen


Sarcopenia. Doctor holds a tablet computer in his hand. Close up. Text is on the display. Blue Background | Image credit: © MQ-Illustrations - © stock.adobe.com

AI Can Help Diagnose Sarcopenia in Patients with Head and Neck Cancer

August 18th 2023
Article

Researchers are using artificial intelligence to diagnose sarcopenia in patients with head and neck cancer.

Read More


Site Logo

A Powerful Voice in Head and Neck Cancer

April 16th 2020
Podcast

This week on the CURE Talks Cancer podcast, we spoke with voice actor Rob Paulsen, who was diagnosed with stage 3 metastatic squamous cell carcinoma in 2016, about how his experience helped him find a reason to smile, even when times get tough.

Listen


Radiotherapy Technique May Prevent Swallow Dysfunction in Head and Neck Cancer

Radiotherapy Technique May Prevent Swallow Dysfunction in Head and Neck Cancer

August 8th 2023
Article

Patients with head and neck cancer treated with dysphagia-optimized intensity-modulated radiotherapy had improved swallow function compared with those treated with standard intensity-modulated radiotherapy.

Read More


triple-negative breast cancer cell

Ongoing Trial Investigates Cancer Vaccine Plus Keytruda for TNBC

August 7th 2023
Article

An ongoing phase 1 trial is analyzing the use of a novel cancer vaccine plus the immunotherapy agent, Keytruda, for patients with triple-negative breast cancer.

Read More

About
Advertise / Support
Contact
CancerNetwork.com
TargetedOnc.com
OncLive.com
OncNursingNews.com
Terms & Conditions
Privacy
Do Not Sell My Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.